openPR Logo
Press release

Ibogaine Clinic Leadership Finalizes Conference Strategy, Emphasizes Personalized Treatment and Future Research

05-05-2025 09:02 PM CET | Health & Medicine

Press release from: ABNewswire

Ibogaine Clinic Leadership Finalizes Conference Strategy,

CORAL SPRINGS, FL - May 5, 2025 - Key leadership from Ibogaine Clinic, including Gavriel Dardashti, Cole Barressi, and Misty Huckabey, convened recently to strategically plan their participation in an upcoming industry conference. The meeting focused on optimizing the clinic's presence, showcasing their unique treatment methodologies, and outlining plans for future data collection and research.

Discussions centered on preparations for the conference booth, including ensuring consistent coverage and finalizing marketing materials. The team plans to utilize compelling visuals, including YouTube patient testimonials and a demonstration of proprietary software developed by Gavriel Dardashti designed to calculate personalized Ibogaine dosages based on various individual factors. Cole Barressi highlighted the clinic's commitment to tailored treatment protocols and the integration of various therapeutic modalities to support patient recovery.

The meeting also served to integrate Misty Huckabey, who brings experience in psychology and ketamine-assisted psychotherapy, into the conference planning. Misty Huckabey, currently pursuing doctoral studies focused on psychedelic treatments, expressed strong alignment with the clinic's mission. Logistical details for her participation, including contact information handling via the clinic's main line, were addressed.

A significant portion of the meeting was dedicated to discussing the clinic's treatment philosophy and observed outcomes. The team noted anecdotal evidence of Ibogaine's positive effects on conditions including addiction, burnout, PTSD, ADHD, and Autism, often linked to underlying trauma and toxicity. The critical role of post-treatment integration, potentially incorporating nature-based therapies, was emphasized as a key component of the clinic's comprehensive approach.

Recognizing the importance of empirical evidence, the leadership discussed plans to enhance data collection efforts. Gavriel Dardashti proposed utilizing brainwave monitoring devices to gather objective post-treatment data. Misty Huckabey, with her background in statistics, is anticipated to play a key role in analyzing this data in the future, contributing to the clinic's research goals and potentially collaborating with external researchers.

Next steps include finalizing conference materials, setting up communication channels for Misty Huckabey, ensuring thorough understanding of treatment protocols among the team, and acquiring technology for data collection and booth demonstration. A follow-up meeting is scheduled before the conference to finalize all preparations.

About Ibogaine Clinic:

Ibogaine Clinic is dedicated to providing advanced and personalized Ibogaine treatment protocols. Focusing on integrated therapies and addressing root causes such as trauma and toxicity, the clinic aims to support individuals seeking recovery from addiction and various neurological and psychological conditions. The clinic is committed to ongoing research and development to further understand and optimize the therapeutic potential of Ibogaine

Media Contact
Company Name: Ibogaine By David Dardashti
Contact Person: Cole Barressi
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ibogaine-clinic-leadership-finalizes-conference-strategy-emphasizes-personalized-treatment-and-future-research]
Country: United States
Website: http://www.ibogaineclinic.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ibogaine Clinic Leadership Finalizes Conference Strategy, Emphasizes Personalized Treatment and Future Research here

News-ID: 4000045 • Views:

More Releases from ABNewswire

Acute Myeloid Leukemia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm
Acute Myeloid Leukemia Market to Evolve Rapidly Over the Next Decade by 2034, De …
The Key Acute Myeloid Leukemia Companies in the market include - SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, and others. The Acute Myeloid Leukemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Myeloid Leukemia pipeline products will significantly revolutionize the Acute Myeloid Leukemia market dynamics. DelveInsight's
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, De …
The Key Pancreatic Cancer Companies in the market include - AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others. The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and
Hereditary Transthyretin Amyloidosis (hATTR) Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Eidos, Corino, Prothena, Ionis Pharma, AstraZeneca, Novo Nordisk
Hereditary Transthyretin Amyloidosis (hATTR) Market to Witness Promising Upswing …
The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, Intellia Therapeutics, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others. DelveInsight's "Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany,
Metastatic HR+/HER2 Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro
Metastatic HR+/HER2 Breast Cancer Market Positioned for Accelerated Development …
The Key Metastatic HR+/HER2 Breast Cancer Companies in the market include - Novartis, Arvinas, Olema Pharmaceuticals, Sichuan Baili Pharmaceutical, Ana C Garrido-Castro, MD, Fudan University, SynDevRx, Inc., Gilead Sciences, Puma Biotechnology, Inc., Adrienne G. Waks, Carrick Therapeutics Limited, and others. DelveInsight's "Metastatic HR+/HER2 Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Metastatic HR+/HER2 Breast Cancer, historical and forecasted epidemiology as well as the Metastatic

All 5 Releases


More Releases for Ibogaine

Ibogaine by David Dardashti to Illuminate the Transformative Ibogaine Experience …
DENVER, CO - June 20, 2024 - Ibogaine by David Dardashti, a pioneer in holistic Ibogaine therapy, is proud to announce its prominent participation on Day 2 of the highly anticipated Psychedelic Conference 2025. David Dardashti and his team will offer individual descriptions of the unique Ibogaine experience, providing invaluable insights for each and every person at the conference seeking information regarding profound and lasting healing from addiction, trauma, and
Ibogaine By David Dardashti is Pioneering Brain Wave Research in Ibogaine Treatm …
Renowned ibogaine expert David Dardashti is embarking on groundbreaking research measuring brain wave activity before and after ibogaine treatment. This study aims to shed light on ibogaine's impact on brain function and its potential to promote a more balanced and fulfilling life. Brain waves are electrical impulses that are produced by the brain and can be measured using an electroencephalogram (EEG). There are four main types of brain waves: alpha, beta,
Ibogaine By David Dardashti Initiates Ibogaine Data Storage on Google Cloud
Ibogaine By David Dardashti a leading psychedelic treatment center, today announced the commencement of ibogaine patient data storage and analysis on the Google Cloud platform. This initiative aims to leverage machine learning to enhance the precision and safety of ibogaine dosing based on past patient outcomes. Ibogaine, a naturally occurring psychoactive substance, has shown promise in treating opioid addiction and other mental health conditions. However, its administration requires careful dosing due
Ibogaine by David Dardashti Offers Proprietary Software to Accelerate Ibogaine R …
Ibogaine by David Dardashti, a renowned pioneer in ibogaine treatment and research, has recently made an exciting announcement regarding the availability of its proprietary software. This software is being offered to contribute to the donations made by Google co-founder towards ibogaine research specifically focused on traumatic brain injury. This potential for collaboration between Ibogaine by David Dardashti and Google co-founder's donations signifies a significant step forward in the field of ibogaine
Ibogaine By David Dardashti's Ibogaine Therapy Revolutionized by Questineers' SQ …
Ibogaine By David Dardashti, a leading innovator in the field of ibogaine therapy, today announced a groundbreaking advancement in the optimization of his ibogaine treatment software. Dardashti's software has revolutionized the way patient data is analyzed by utilizing the power of SQL. Instead of manually sifting through mountains of data, healthcare providers can now simply ask the software specific questions to extract the information they need. This streamlined approach not only
Ibogaine By David Dardashti Incorporates SQL into Ibogaine Software for Enhanced …
Ibogaine By David Dardashti, a leading provider of innovative solutions in the field of ibogaine therapy, today announced the integration of SQL (Structured Query Language) into its proprietary ibogaine software. This development marks a significant step forward in leveraging the power of data analysis to optimize the ibogaine algorithm for enhanced treatment outcomes With the integration of SQL, Ibogaine By David Dardashti has significantly enhanced its ability to analyze a vast